home / stock / edit / edit short
Short Information | Editas Medicine Inc. (NASDAQ:EDIT)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 8,422,091 |
Total Actual Volume | 51,920,313 |
Short Trends | |
---|---|
Cover Days | 20 |
Short Days | 0 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 421,105 |
Average Short Percentage | 18.01% |
Is there a EDIT Short Squeeze or Breakout about to happen?
See the EDIT Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-03-2024 | $4.6 | $4.66 | $4.7399 | $4.56 | 987,594 | 164,939 | 16.7% |
07-02-2024 | $4.61 | $4.54 | $4.63 | $4.45 | 1,545,916 | 374,748 | 24.24% |
07-01-2024 | $4.66 | $4.61 | $4.86 | $4.57 | 1,733,399 | 473,168 | 27.3% |
06-28-2024 | $4.76 | $4.67 | $4.83 | $4.59 | 3,931,842 | 431,346 | 10.97% |
06-27-2024 | $4.83 | $4.74 | $4.85 | $4.685 | 2,286,605 | 456,870 | 19.98% |
06-26-2024 | $4.97 | $4.81 | $4.9781 | $4.78 | 2,126,453 | 505,047 | 23.75% |
06-25-2024 | $5.04 | $4.97 | $5.125 | $4.94 | 2,222,498 | 372,010 | 16.74% |
06-24-2024 | $5.15 | $5.08 | $5.39 | $5.0306 | 1,859,972 | 244,268 | 13.13% |
06-21-2024 | $5.06 | $5.11 | $5.23 | $4.99 | 9,043,208 | 398,448 | 4.41% |
06-20-2024 | $5.06 | $5.04 | $5.11 | $4.89 | 2,327,091 | 437,971 | 18.82% |
06-18-2024 | $5.29 | $5.04 | $5.31 | $4.965 | 3,576,435 | 764,038 | 21.36% |
06-17-2024 | $5.11 | $5.07 | $5.11 | $4.815 | 3,422,350 | 938,371 | 27.42% |
06-14-2024 | $5.46 | $5.06 | $5.4898 | $5.03 | 3,328,649 | 710,857 | 21.36% |
06-13-2024 | $5.98 | $5.49 | $6.07 | $5.49 | 2,075,292 | 341,245 | 16.44% |
06-12-2024 | $5.71 | $6.04 | $6.22 | $5.65 | 3,278,736 | 383,498 | 11.7% |
06-11-2024 | $5.3 | $5.43 | $5.52 | $5.13 | 1,507,344 | 248,802 | 16.51% |
06-10-2024 | $5.2 | $5.32 | $5.33 | $5.04 | 1,977,152 | 386,010 | 19.52% |
06-07-2024 | $5.39 | $5.3 | $5.415 | $5.265 | 1,460,634 | 153,955 | 10.54% |
06-06-2024 | $5.57 | $5.43 | $5.61 | $5.4 | 1,132,848 | 219,698 | 19.39% |
06-05-2024 | $5.81 | $5.6 | $5.93 | $5.475 | 2,096,295 | 416,802 | 19.88% |
News, Short Squeeze, Breakout and More Instantly...
All patients treated in the RUBY trial are free of vaso-occlusive events post- renizgamglogene autogedtemcel (reni-cel) infusion Patients had early normalization of total hemoglobin with a mean within the normal range at >14 g/dL and rapid and sustained improvements in fetal ...
All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post- renizgamglogene autogedtemcel (reni-cel) infusion Reni-cel was well-tolerated and demonstrated a safety profile consistent with myeloablative con...